Background: The clinicoepidemiologic relevance of moderately elevated concentrations of circulating beta(2)-microglobulin (beta(2)-M) has not been established.
Methods: We examined whether serum beta(2)-M concentration independently predicts total mortality in community-dwelling older populations and compared its predictive value with that of cystatin C and C-reactive protein (CRP) using a prospective cohort study of 1034 initially nondisabled persons 65 years and older as part of the Tokyo Metropolitan Institute of Gerontology Longitudinal Interdisciplinary Study on Aging. Cox proportional hazards models were used to examine independent associations between baseline beta(2)-M levels and total mortality.
Results: During a median follow-up of 7.9 years, 223 persons died. A strong dose-response relationship was found between baseline serum beta(2)-M concentration and mortality risk, even after multiple adjustments. Compared with individuals in the lowest tertile of serum beta(2)-M concentration, those in the middle (hazard ratio, 2.02; 95% confidence interval [CI], 1.35-3.04) and highest (hazard ratio, 2.84; 95% CI, 1.92-4.20) tertiles had a substantially increased mortality risk. Respective values were 1.28 (95% CI, 0.86-1.90) and 1.95 (95% CI, 1.31-2.89) for cystatin C and 1.39 (95% CI, 0.98-1.98) and 1.44 (95% CI, 1.00-2.06) for CRP; only the highest tertiles showed significantly higher mortality risks. The area under the receiver operating characteristic curve for 8-year mortality was greatest for beta(2)-M (0.70; 95% CI, 0.66-0.74), followed by cystatin C (0.66; 95% CI, 0.62-0.70) and CRP (0.57; 95% CI, 0.53-0.61). Additional adjustment for renal function measures, inflammation markers, or both only partially reduced the association between beta(2)-M and mortality.
Conclusion: Serum beta(2)-M is an independent predictor of total mortality in a general population of older adults and may be a better predictor than cystatin C or CRP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archinternmed.2007.64 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma.
Eur J Radiol Open
December 2024
Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
Objectives: To investigate the correlations between IMPeTUs-based 18 F-FDG PET/CT parameters and clinical features in patients with newly diagnosed multiple myeloma (MM).
Materials And Methods: PET/CT were analysed according to the IMPeTUs criteria. We correlated these PET/CT parameters with known clinically relevant features, bone marrow plasma cell (BMPC) infiltration rate and the presence of cytogenetic abnormalities.
Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Tumour Biol
March 2024
Department of Laboratory Medicine, Althaia Xarxa Assistencial Universitària de Manresa, Manresa, Catalonia, Spain.
Article Synopsis
- Tumor markers (TMs) are special molecules that help doctors find out if someone has cancer and how they're doing treatment.
- Sometimes these markers can show up even when a person is healthy, which can lead to doctors thinking there's a problem when there's not.
- The review looks at many studies from 1970 to 2023 to understand why false results happen and how knowing more about these markers can help doctors make better decisions.
Disease severity and renal function among sickle cell anaemia patients in a tertiary hospital, South-south, Nigeria: a cross sectional study.
Malawi Med J
March 2023
Department of Chemical Pathology, University of Ilorin, Ilorin.
Background: Renal disease is a recognized complication of sickle cell anaemia (SCA), especially from the third decade of life and is linked to disease severity. This study assessed the association between disease severity and renal function among SCA patients using routine and newer markers of renal function.
Methods: This cross-sectional study recruited 85 SCA patients.
Gut microbial metabolite TMAO increases peritoneal inflammation and peritonitis risk in peritoneal dialysis patients.
Transl Res
February 2022
State Key Laboratory of Organ Failure Research, National Clinical Research Center of Kidney Disease, Key Laboratory of Organ Failure Research (Ministry of Education), Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China. Electronic address:
Trimethylamine-N-oxide (TMAO), a gut microbiota-produced metabolite, is accumulated in chronic kidney disease (CKD) patients. It is well known to contribute to CKD-related cardiovascular complications. However, the effect of TMAO on peritoneal dialysis (PD)-related peritonitis remains largely unknown.
View Article and Find Full Text PDFSerum beta-2 microglobulin analysis in patients with oral squamous cell carcinoma.
Natl J Maxillofac Surg
July 2021
Department of Oral and Maxillofacial Surgery, Yenepoya Dental College, Mangalore, Karnataka, India.
Aim: This study aims to compare the level of serum beta-2 microglobulin (β2-M) in normal healthy individuals and patient with squamous cell carcinoma (SCC).
Methodology: This study has been conducted in patients attending the Department of Oral and Maxillofacial Surgery, Yenepoya Dental College, Deralakatte, Mangalore. Sample comprises of 25 cases of clinically and histologically diagnosed oral cancer and 25 normal healthy individuals as control group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!